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Talks on rare diseases in the field of neurology often start with a statement like this: “About 
80% of all rare diseases have a neurologic manifestation and about 80% of those are genetic 
in origin”. Although these numbers probably represent more of an estimate than well-
documented evidence, rapidly advancing and cost-effective sequencing technologies have led 
to the quickly growing identification of patients with hereditary neurological diseases. While 
the importance of genetics for diagnosis and genetic counseling is undisputed, the recent 
development of first gene-targeted therapies entering clinical trial1,2 is adding an important 
new layer to the (re-)consideration of genetic testing in neurology. However, establishing 
accurate genotype-phenotype and genotype-treatment relationships requires large sample 
sizes. Systematic reviews can serve as instruments to combine information from several small 
samples, but unfortunately, this is often complicated by inconsistent and incomplete reporting 
of clinical and genetic data across studies. Thus, large multi-center approaches are necessary 
to systematically and uniformly characterize patients with genetic neurologic conditions and 
to eventually establish sizable clinical trial-ready cohorts. 
 
Using genetic Parkinson’s disease (PD) as an example and Illustrating the magnitude of the 
issue, up to ~300,000 patients worldwide are estimated to have hereditary forms of PD, 
representing 5% of an estimated total of 6 million patients with PD in 20183. Monogenic forms 
of Parkinson’s disease (PD) can be caused by mutations in SNCA, LRRK2, VPS35, Parkin, PINK1, 
and DJ14. These genes have been unequivocally linked to PD according to the criteria 
established by the International Parkinson and Movement Disorder Society Task Force on 
Genetic Nomenclature in Movement Disorders5. In addition, GBA variants represent the 
strongest known genetic risk factor for PD, with an age-dependent penetrance of ~30% at the 
age of 80 years6. However, individual clinical information for patients with genetic PD is only 
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reported for a fraction of cases (n=1,769; Movement Disorder Society Genetic mutation 
database; MDSGene, www.mdsgene.org) in the international medical literature and 
publications are often biased towards unusual presentations of gene mutations. Both clinical 
expression and penetrance of gene mutations may vary considerably across different 
populations and ethnicities7,8, further challenging pooling of data and their interpretation. 
Finally, given the growing availability of diagnostic genetic testing and the increasing difficulty 
to publish case reports of mutation carriers in peer-reviewed journals, we expect the 
proportion of published vs. unpublished cases to rapidly shift towards the latter.  
As a result, neurologists commonly lack reliable reference data to be able to offer tailored 
counseling and treatment to patients with genetic PD and other hereditary neurological 
diseases.  
 
Since the 1990s, there has been a growing interest and investment in large-scale, team-
based research initiatives to address complex and multifaceted problems that require 
collaboration across different disciplines9. Likewise, there is an increasing necessity for – 
ideally global-scale - team science approaches of clinicians and researchers with similar 
interests joining forces to promote advanced research and to improve patient care.  
Employing novel ways of team science, electronic databases, and global communication, we 
performed a worldwide survey of genetic PD with an emphasis on availability of 
demographic, clinical, omics and imaging data as well as of biomaterials, to both foster and 
exploit global collaboration. In order to identify possible participants for our survey, we 
compiled the names of corresponding authors from articles included in the Movement 
Disorder Society Genetic mutation database (MDSGene, www.mdsgene.com) that 
comprises the following PD genes: SNCA, LRRK2, VPS35, Parkin, PINK1, and DJ17,8. For GBA, 
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we screened the literature according to MDSGene criteria to identify corresponding authors 
of eligible articles (articles published in English with clinical information available). In 
addition, the “Genetic Epidemiology of Parkinson’s disease” consortium 
(https://geopd.lcsb.uni.lu) contributed names of members not already identified as a 
corresponding author of publications represented in MDSGene. Additional contacts were 
included upon recommendation of participants (Figure 2). We next developed an online 
survey and invited the previously identified researchers to report availability of information 
on their genetic PD patients. To avoid multiple reporting of the same cases, we asked 
participants to indicate sharing of samples and encouraged participants from the same 
center to nominate one person to report all cases or to divide up the cases between 
reporting researchers. The survey was open for contributions for 5 weeks from March until 
May 2018. Two rounds of email reminders were sent out after two weeks each to enhance 
the response rate. Participants received no financial compensation for their contribution. 
A total of 103 researchers from different centers in 43 countries reported n=8,453 PD patients 
with mutations in PD genes (Figure 1, for more details please see Supplementary Table 2). The 
overall response rate to our invitation was 45% and 79% of the respondents completed the 
survey. Of these, 98% indicated their interest in further collaboration, and 45% sent personal 
emails expressing their interest to contribute further to this project and/or suggesting 
additional collaborative projects (Figure 2). Reflecting the worldwide distribution of 
participating centers, the backgrounds of the reported patient samples were diverse and 
include Arab, Asian, Ashkenazi Jewish, Caucasian, Hispanic, Indian, Mennonites, and North 
African. Almost equal numbers of patients (n=~3000) were reported to carry mutations in 
LRRK2 or a GBA risk allele, followed by pathogenic variants in Parkin (n=~1500), SNCA and 
PINK1 (n=~250 each), DJ1 and VPS35 (n=~30 each). The total number of reported monogenic 
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PD cases in the present study exceeds published cases by a factor of 2.6 (n=5,299 vs. n=2,064 
cases (www.mdsgene.org), both excluding GBA) indicating that the majority of patients with 
genetic PD are not reflected in the published literature. Regarding data quality and 
completeness, information on PD nonmotor signs is particularly scarce in the literature. Even 
for cognition, published information is available only for about a third of the cases with 
monogenic PD (www.mdsgene.org)7,8. In contrast, our present approach indicates availability 
of nonmotor signs in general for two thirds of the reported cases (Table 1).  
To fill these knowledge gaps, a new collaborative mindset is indispensable. Our worldwide 
collaborative effort revealed an unprecedented level of data completeness, a paramount 
prerequisite when aiming to perform meaningful genotype-phenotype correlations and when 
selecting patients for clinical studies and trials7,8. Team science of clinicians and researchers in 
the field of rare neurological diseases will facilitate sharing of expertise, promote new 
research opportunities, offer a network to foster new training opportunities for young 
researchers, and, advance development of individualized therapies. As a future perspective, 
collecting very large cohorts of monogenic PD may result in powerful enough data sets to 
perform meaningful natural history studies of individual monogenic forms as well as modifier 
studies. These can be modeled after studies performed in well-characterized longitudinal 
cohorts unselected for genetic cause10. In a similar vein, our approach may be expanded to 
mutation-negative early-onset PD patients with a positive family history in order to uncover 
rare novel mutations. 
Based on the enthusiastic responses to our survey and the eager willingness to collaborate, 
we are confident that we have successfully established a team science approach that will 
specifically enable i) successfully increasing sample sizes of patients with rare neurological 
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Figure 1: Worldwide centers reporting patients with monogenic PD and PD patients with 
variants in GBA.  
Legend: Please find a detailed list of the participating members of the MJFF Global Genetic 
Parkinson’s Disease Study Group in Supplementary Online Table 1.  
 11 
 
Figure 2: Response analysis.  
 




Table 1: Availability of information.  
 
Legend: The participating centers were asked to report availability of an item if the relating 
data was available for at least a subset of the reported PD patients registered at their center. 
 
 
number of centers 
reporting available 
information 
(percentage of total 
participating centers 
(n=103)) 
Age 102 (99%) 
Sex 102 (99%) 
Ethnicity 101 (98%) 
Pedigree 94 (91%) 
Age at onset 97 (94%) 
Unified Parkinson Disease Rating Scale 
(UPDRS) 68 (66%) 
Hoehn & Yahr Scale 75 (73%) 
Dopaminergic medications 79 (77%) 
Nonmotor signs 68 (66%) 
Environmental exposures 48 (47%) 
Life style variables 36 (35%) 
Treatment response 76 (74%) 
Omics data 17 (17%) 
-Genomics 14 (14%) 
-Transcriptomics 2 (2%) 
-Proteomics 1 (1%) 
-Metabolomics 1 (1%) 
Imaging 38 (37%) 
-MRI 33 (32%) 
-SPECT/PET 19 (18%) 
-TCS 7 (7%) 
DNA 88 (85%) 
RNA 22 (21%) 
Serum 28 (27%) 
Plasma 26 (25%) 
Whole blood 23 (22%) 
Cerebrospinal fluid 8 (8%) 
Fibroblasts 12 (12%) 
iPSCs 11 (11%) 
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Jan Aasly MD Department of Neurology, St. Olavs Hospital, Trondheim, 
Norway; 
Department of Neuroscience, Norwegian University of 
Science and Technology, Trondheim, Norway 
Charles Adler MD, 
PhD 
Department of Neurology, Mayo Clinic College of Medicine, 
Scottdale, Arizona, USA 
Azlina Ahmad-
Annuar 
PhD Biomedical Science, University of Malaya, Kuala Lumpur, 
Malaysia 
Alberto Albanese MD Department of Neurology, IRCCS Istituto Clinico Humanitas, 
Rozzano, Milano, Italy; 
Department of Neurology, Catholic University, Milano, Italy 
Roy Alcalay MD, 
MS 
Department of Neurology, Columbia University, New York, 
New York, USA 
Bashayer Al-
Mubarak 
PhD Behavioural genetics Unit, Department of Genetics, 
Research Centre, King Faisal Specialist Hospital and 
Research Center, Riyadh, Saudi Arabia 
Victoria Alvarez PhD Laboratório de Genética, Hospital Universitario Central de 
Asturias, Oviedo, Asturias, Spain 
Brennie Andree-
Muñoz 
MD Department of Neurology, Hospital Luis Vernaza, Guayaquil, 
Equador 
Grazia Annesi PhD Institute of Molecular Bioimaging and Physiology, National 
Research Council, Germaneto, Cantazaro, Italy 
Silke Appel-
Cresswell 
MD Pacific Parkinson’s Research Centre, Division of Neurology, 
Department of Medicine, Vancouver, British Columbia, 
Canada 
David Arkadir MD, 
PhD 
Department of Neurology, Hadassah Medical Center and 
the Hebrew University, Jerusalem, Israel 
Sebastian Armasu MSc Division of Biomedical Statistics and Informatics, 
Department of Health Sciences Research, Mayo Clinic, 
Rochester, Minnesota, USA 
Thomas R. Barber MD Oxford Parkinson’s Disease Centre, Nuffield Department of 
Clinical Neuroscience, University of Oxford, Oxford, 
Oxfordshire, United Kingdom 
Soraya Bardien MD Division of Molecular Biology and Human Genetics, Faculty 
of Medicine and Health Sciences, Stellenbosch University, 




PhD DST/NWU Preclinical Drug Development Platform, North-
West University, Potchefstroom, North-West, South Africa 
Matthew J. Barrett MD Department of Neurology, University of Virginia, 
Charlottesville, Virginia, USA 
A. Nazlı Başak PhD Department of Molecular Biology and 
Genetics, Koç University School of Medicine, KUTTAM, Suna 
and Inan Kıraç Foundation, NDAL, Istanbul, Turkey 
Thomas Beach MD, 
PhD 
Civin Laboratory of Neuropathology, Banner Sun Health 
Research Institute, Sun City, Arizona, USA 
Bruno A. Benitez MD Department of Psychiatry, Washington University in Saint 
Louis, Saint Louis, Missouri, USA 
Daniela Berg MD Department of Neurology, Christian-Albrechts-Universität, 
Kiel, Germany 
Kailash Bhatia MD Clinical Movement Disorders, UCL Institute of Neurology, 
University College London, London, United Kingdom; 
Clinical Neurology, National Hospital for Neurology, 
University College London, London, United Kingdom 
Ferdinand Binkofski MD Clinical Cognitive Research, Department of Neurology, 
University Hospital RWTH Aachen, Aachen, Germany; 
Institute for Neuroscience and Medicine (INM-4), Research 
Center Juelich, Juelich, Germany 
Cornelis 
Blauwendraat 
PhD Laboratory of Neurogenetics, National Institute on Ageing, 
National Institutes of Health, Bethesda, Maryland, USA 
Vincenzo Bonifati MD, 
PhD 
Department of Clinical Genetics, Erasmus MC, University 
Medical Center Rotterdam, Rotterdam, Netherlands 
Vanderci Borges MD Department of Neurology, Universidade Federal de São 
Paulo, São Paulo, Brazil 
Maria Bozi MD, 
PhD 
Parkinson's and Movement Disorders Unit, Attiko Hospital, 
University of Athens, Haidari, Athens, Greece; 
Department of Neurology, Athens Psychiatry Hospital, NHS, 
Haidari, Athens, Greece 
Alexis Brice MD ICM, Institut du Cerveau et de la Moelle épinière, Paris, 
France; 
UMR 1127, NS-PARK/FCRIN, Inserm, Paris, France; 
Sorbonne Université, Paris, France; 
UMR 7225, CNRS, Paris, France; 
Department of Genetics, Hôpital Pitié-Salpêtrière, 
Assistance Publique Hôpitaux de Paris, Paris, France 
Laura Brighina MD, 
PhD 
Department of Neurology, Milan Center for Neuroscience, 
University of Milano-Bicocca/San Gerardo Hospital, Monza, 
Monza Brianza, Italy 
Kathrin Brockmann MD Department of Neurodegenerative Diseases, University of 
Tuebingen, Tuebingen, Baden Wuerttemberg, Germany; 
Hertie Institute for Clinical Brain Research and German 





MD Institute of Neurogenetics, University of Luebeck, Luebeck, 
Germany; 
Department of Neurology, University of Luebeck, Luebeck, 
Germany 
Marta Camacho MSc Department of Clinical Neurosciences, University of 
Cambridge, Cambridge, United Kingdom 
Francisco Cardoso MD, 
PhD 
Department of Internal Medicine, UFMG, Belo Horizonte, 
Minas Gerais, Brazil 
Andrea Carmine 
Belin 
PhD Department of Neuroscience, Karolinska Institutet, 
Stockholm, Sweden 
Jonathan Carr MD Division of Neurology, Department of Medicine, Faculty of 
Medicine and Health Sciences, Stellenbosch University, 
Cape Town, South Africa 
Piu Chan MD, 
PhD 
Department of Neurobiology and Neurology, Capital 
Medical University, Xuanwu Hospital, Beijing, Beijing, China 
Jorge Chang-
Castello 
MD Department of Molecular Biology, Hospital Luis Vernaza, 
Guayaquil, Ecuador 
Bruce Chase PhD Department of Biology, University of Nebraska at Omaha, 
Omaha, Nebraska, USA 
Alice Chen-Plotkin MD Department of Neurology, University of Pennsylvania, 
Philadelphia, Pennsylvania, USA 
Sun Ju Chung MD, 
PhD 
Medical Genetic Center, Department of Neurology, Asan 
Medical Center, University of Ulsan College of Medicine, 
Seoul, South Korea 
Roberto Cilia MD ASST Pini-CTO, Parkinson Institute, Milan, Milan, Italy 
Jordi Clarimon PhD Department of Neurology, Biomedical Research Institute 
IIB-Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, 
Spain; 
Centro de Investigación Biomédica en Red sobre 
Enfermedades Neurodegenerativas (CIBERNED), Madrid, 
Spain 
Lorraine Clark PhD Department of Pathology and Cell Biology, Vagelos College 
of Physicians & Surgeons, Columbia University Irving 
Medical Center, New York, New York, USA; 
Taub Institute for Research on Alzheimer's Disease and the 
Aging Brain, Columbia University Irving Medical Center, New 
York, New York, USA; 
Laboratory of Personalized Genomic Medicine, Vagelos 
College of Physicians & Surgeons, Columbia University Irving 
Medical Center, New York, New York, USA 
Mario Cornejo-
Olivas 
MD Neurogenetics Research Center, Instituto Nacional de 
Ciencias Neurologicas, Lima, Peru; 
Center for Global Health, Universidad Peruana Cayetano 
Heredia, Lima, Peru 
Jean-Christophe 
Corvol 
MD ICM, Institut du Cerveau et de la Moelle épinière, Paris, 
France; 
UMR 1127, NS-PARK/FCRIN, Inserm, Paris, France; 
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Sorbonne Université, Paris, France; 
UMR 7225, CNRS, Paris, France; 
Department of Genetics, Hôpital Pitié-Salpêtrière, 
Assistance Publique Hôpitaux de Paris, Paris, France 
Carlos Cosentino MD Neurogenetics Research Center, Instituto Nacional de 
Ciencias Neurologicas, Lima, Peru; 
School of Medicine, Universidad Nacional Mayor de San 
Marcos, Lima, Peru 
Patrick Cras MD, 
PhD 
Department of Neurology, Antwerp University Hospital, 
Edegem, Belgium; 
Born Bunge Institute, Department of Neurology, University 
of Antwerp, Wilrijk, Belgium 
David Crosiers MD, 
PhD 
Department of Neurology, Antwerp University Hospital, 
Edegem, Belgium; 
Born Bunge Institute, Department of Neurology, University 
of Antwerp, Wilrijk, Belgium; 
Center for Molecular Neurology, VIB, Wilrijk, Belgium 
Joana Damásio MD Department of Neurology, Hospital de Santo António - 
Centro Hospitalar do Porto, Porto, Portugal 
Parimal Das PhD Centre for Genetic Disorders, Institute of Science, Banaras 





Department of Neurology, Universidade Federal de São 
Paulo, São Paulo, Brazil; 
Instituto Israelita de Ensino e Pesquisa, Hospital Israelita 
Albert Einstein, São Paulo, Brazil 
Giuseppe De 
Michele 
MD Department of Neurosciences and Reproductive and 
Odontostomatological Sciences, Federico II University, 
Naples, Italy 
Anna De Rosa MD, 
PhD 
Department of Neurosciences and Reproductive and 
Odontostomatological Sciences, Federico II University, 
Naples, Italy 
Elena Dieguez MD Neurology Institute, Universidad de la Republica, 
Montevideo, Uruguay 
Jolanta Dorszewska MD, 
PhD 
Laboratory of Neurobiology, Department of Neurology, 
Poznan University of Medical Sciences, Poznan, Poland 
Sevda Erer MD Department of Neurology, Uludag University, Neurology, 
Bursa, Turkey 
Sibel Ertan MD Department of Neurology, Istanbul University, Cerrahpaşa 
School of Medicine, Istanbul, Turkey 
Matthew Farrer PhD Centre for Applied Neurosciences, University of British 
Columbia, Vancouver, British Columbia, Canada 
Ekaterina Fedotova MD, 
PhD 
Department of Neurogenetics, Research Center of 
Neurology, Moscow, Russia 
Rosangela Ferese PhD IRCCS Neuromed, Localita‘ Camerelle, Pozzilli, Isernia, Italy 
Carlo Ferrarese MD Department of Neurology, Milan Center for Neuroscience, 
University of Milano-Bicocca/San Gerardo Hospital, Monza, 
Monza Brianza, Italy 
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Henrique Ferraz MD Department of Neurology, Universidade Federal de São 
Paulo, São Paulo, Brazil 
Ondrej Fiala MD, 
PhD 
Department of Neurology, Institute of Neuropsychiatric 
Care (INEP), Prague, Czech Republic 
Tatiana Foroud PhD Department of Medical and Molecular Genetics, Indiana 
University School of Medicine, Indianapolis, Indiana, USA 
Andrzej Friedman MD, 
PhD 
Department of Neurology, Medical University in Warsaw, 
Warsaw, Poland 
Roberta Frigerio MD Department of Neurology, NorthShore University 
HealthSystem, Evanston, Illinois, USA 
Manabu Funayama PhD Research Institute for Diseases of Old Age, Graduate School 
of Medicine, Juntendo University, Bunkyo, Tokyo, Japan 
Stefano 
Gambardella 
PhD IRCCS Neuromed, Localita‘ Camerelle, Pozzilli, Isernia, Italy 
Gaetan Garraux MD, 
PhD 
Department of Neurology, Centre Hospitalier Universitaire 
(CHU) de Liège, Liège, Belgium; 
MoVeRe group, GIGA-CRC in vivo imaging, University of 
Liege, Liège, Belgium 
Emilia M. Gatto MD Movement Disorders, Department of Neurology, Instituto 
de Neurosciencias Buenos Aires, Buenos Aires, Argentina 
Gençer Genç MD Department of Neurology, Şişli Etfal Training and Research 
Hospital, Istanbul, Turkey 
Stefano Goldwurm MD, 
PhD 
ASST Pini-CTO, Parkinson Institute, Milan, Milan, Italy; 
Department of Neuroscience "Rita Levi Montalcini", 





Neurodegenerative diseases, Biocruces Research Institute, 
Biocruces, Barakaldo, Bizkaia, Spain 
Pilar Gómez-Garre PhD Centro de Investigación Biomédica en Red sobre 
Enfermedades Neurodegenerativas (CIBERNED), Madrid, 
Spain; 
Unidad de Trastornos del Movimiento, Servicio de 
Neurología y Neurofisiología Clínica, Hospital Universitario 
Virgen del Rocío/CSIC/Universidad de Sevilla, Instituto de 
Biomedicina de Sevilla, Seville, Seville, Spain 
Ana Gorostidi PhD Genomics Platform, Biodonostia Research Institute, San 
Sebastian, Gipuzkoa, Spain; 
Neuroscience Area, Biodonostia Research Institute, San 
Sebastian, Gipuzkoa, Spain 
Donald Grosset MD Institute of Neurological Sciences, NHS Greater Glasgow & 
Clyde, Queen Elizabeth University Hospital, Glasgow, 
Scotland, United Kingdom; 
Institute of Neuroscience & Psychology, University of 
Glasgow, Glasgow, Scotland, United Kingdom 
Hasmet Hanagasi MD Department of Neurology, Istanbul Faculty of Medicine, 
Istanbul University, Istanbul, Turkey 
John Hardy MD Neurodegenerative Disease, University College London, UCL 
Institute of Neurology, London, United Kingdom 
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Anhar Hassan MD Department of Neurology, Mayo Clinic, Rochester, 
Minnesota, USA 
Nobutaka Hattori MD, 
PhD 
Department of Neurology, Juntendo University School of 
Medicine, Bunkyo, Tokyo, Japan 
Robert A. Hauser MD Parkinson's Disease and Movement Disorders Center, 
Department of Neurology, University of South Florida, 
Tampa, Florida, USA 
Peter Hedera MD, 
PhD 
Division of Movement Disorders, Department of Neurology, 
Vanderbilt University, Nashville, Tennessee, USA 
Faycal Hentati MD Mongi Ben Hamida National Institute of Neurology, Tunis, 
Tunisia 
Jens Michael Hertz MD Department of Clinical Genetics, Odense University 
Hospital, Odense C, Denmark 
Janice L. Holton MD Queen Square Brain Bank for Neurological Disorders, 
Department of Clinical and Movement Neurosciences, UCL 
Queen Square Institute of Neurology, University College 
London, London, United Kingdom 
Henry Houlden MD Neuromuscular Diseases, UCL Institute of Neurology, 
University College London, London, United Kingdom 
Mara H. Hutz PhD Departamento de Genética, Universidade Federal do Rio 
Grande do Sul, Porto Alegre, Brazil 
Takeshi Ikeuchi MD, 
PhD 
Molecular Genetics, Brain Research Institute, Niigata 
University, Niigata, Niigata, Japan 
Sergey Illarioshkin MD, 
PhD 
Department of Neurogenetics, Research Center of 
Neurology, Moscow, Russia 
Miguel Inca-
Martinez 
BS Neurogenetics Research Center, Instituto Nacional de 
Ciencias Neurologicas, Lima, Peru 
Jon Infante MD, 
PhD 
Department of Neurology, University Hospital Marques de 
Valdecilla, IDIVAL, University of Cantabria, Santander, 
Cantabria, Spain 
Joseph Jankovic MD Parkinson's Disease Center and Movement Disorders Clinic, 
Department of Neurology, Baylor College of Medicine, 
Houston, Texas, USA 
Beom Seok Jeon MD, 
PhD 
Department of Neurology, Seoul National University 
Hospital, Seoul, South Korea 
Silvia Jesús MD, 
PhD 
Centro de Investigación Biomédica en Red sobre 
Enfermedades Neurodegenerativas (CIBERNED), Madrid, 
Spain; 
Unidad de Trastornos del Movimiento, Servicio de 
Neurología y Neurofisiología Clínica, Hospital Universitario 
Virgen del Rocío/CSIC/Universidad de Sevilla, Instituto de 





Department of Neurosciences, Universidad de Antioquia, 
Medellin, Colombia 
Valtteri Kaasinen MD, 
PhD 
Dept. of Neurology and Turku PET Centre, University of 
Turku and Division of Clinical Neurosciences, Turku 
University Hospital, Turku, Finland 
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Meike Kasten MD Institute of Neurogenetics, University of Luebeck, Luebeck, 
Germany 
Department of Psychiatry and Psychotherapy, University of 
Luebeck, Luebeck, Germany 
Hiroshi Kataoka MD Department of Neurology, Nara Medical University, 
Kashihara, Nara, Japan 
Hideshi Kawakami MD, 
PhD 
Epidemiology, Research Institute for Radiation Biology & 
Medicine, Hiroshima University, Hiroshima, Hiroshima, 
Japan 
Yun Joong Kim MD, 
PhD 
ILSONG Institute of Life Science, Hallym University, Anyang-
si, Gyeonggi-do, South Korea;  
Department of Neurology, Hallym University, Anyang-si, 
Gyeonggi-do, South Korea 
Christine Klein MD Institute of Neurogenetics, University of Luebeck, Luebeck, 
Germany 
Péter Klivényi MD Department of Neurology, University of Szeged, Szeged, 
Hungary 
Sulev Koks MD, 
PhD 
The Perron Institute for Neurological and Translational 
Science, Nedlands, Western Australia, Australia 
Inke R. König PhD Institute of Medical Biometry and Statistics, University of 
Luebeck, Luebeck, Germany 
Vladimir Kostić MD Department for Neurodegeneration, Clinic for Neurology 





Department of Neurology, Medical University in Warsaw, 
Warsaw, Poland 
Rejko Krüger MD University of Luxembourg, Esch-sur-Alzette, Luxembourg 
Anna Krygowska-
Wajs 
MD Department of Neurology, Collegium Medicum, Jagiellonian 
University, Krakow, Poland 
Jaime Kulisevsky MD, 
PhD 
Department of Neurology, Biomedical Research Institute 
IIB-Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, 
Spain; 
Centro de Investigación Biomédica en Red sobre 
Enfermedades Neurodegenerativas (CIBERNED), Madrid, 
Spain 
Anthony Lang MD Edmond J. Safra Program in Parkinson's Disease, Division of 
Neurology, Department of Medicine, University of Toronto, 
Toronto Western Hospital, Toronto, Ontario, Canada 
Mark LeDoux MD, 
PhD 
Department of Psychology and School of Health Studies, 
University of Memphis, Memphis,  
Suzanne Lesage MD ICM, Institut du Cerveau et de la Moelle épinière, Paris, 
France; 
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Supplement 2: Number of centers and reported genetic PD patients 
Legend: In total, 103 centers shared numbers of available genetic PD patients (listed in the 
table), and additional 5 centers completed the survey but did not indicate numbers.  
Researchers were asked to report all PD patients with mutations in one of the listed genes 
that were registered at their center. Whether these patients are still available for future 
studies was not assessed, but given the fact that the genes of interest were all described within 
the last two decades, the proportion of historic cases included in these numbers should be 
relatively low. 
 
*Mutations in GBA are considered risk variants for PD. The same applies to certain mutations 
in LRRK2 in the Asian population (e.g. G2385R), which we did not specifically assess in our 
survey, but which centers may have included in the reported numbers.  
 
  centers DJ1 GBA* LRRK2* Parkin PINK1 SNCA VPS35 
Argentina 2 0 0 10 1 0 0 0 
Australia 2 0 0 19 11 3 2 4 
Austria 1 0 30 1 6 1 0 3 
Belgium 2 0 12 43 1 0 1 0 
Brazil 5 0 26 39 34 2 1 0 
Canada 2 2 34 328 65 62 65 3 
China 3 5 90 330 264 10 0 5 
Colombia 1 0 13 3 12 0 0 0 
Denmark 1 0 0 0 2 0 0 0 
Ecuador 1 0 1 0 0 0 0 0 
Estonia 1 0 15 25 5 0 1 5 
Faroe Islands 1 0 0 1 0 0 0 0 
Finland 3 0 15 2 2 0 2 0 
France 1 2 124 189 145 19 27 5 
Germany 4 1 119 20 23 12 2 2 
Greece 2 0 38 1 3 0 77 0 
Hungary 1 0 3 1 0 0 0 0 
India 1 0 6 2 5 3 0 0 
Ireland 1 1 21 2 25 1 0 0 
Israel 2 1 240 180 1 0 0 1 
Italy 9 3 227 147 117 28 22 0 
Japan 4 0 65 20 293 23 19 4 
Malaysia 1 0 0 200 0 0 0 0 
Netherlands 1 1 15 1 3 0 1 0 
Norway 2 0 35 40 5 4 0 0 
Peru 1 0 20 1 1 0 0 0 
Poland 2 0 0 1 42 2 2 0 
Portugal 2 1 0 0 4 1 0 0 





Russia 1 1 32 15 40 2 2 1 
Saudi Arabia 1 1 0 0 15 4 0 0 
Serbia 1 1 78 6 17 1 0 0 
Singapore 1 0 20 0 0 0 0 0 
South Africa 2 0 13 15 19 4 2 0 
Spain 7 2 77 386 72 4 8 0 
Sweden 2 2 37 14 2 0 6 0 
Taiwan 3 1 27 12 30 11 0 2 
Thailand 1 0 24 0 14 0 0 0 
Tunisia 1 0 0 559 10 59 0 0 
Turkey 3 3 2 2 36 2 2 0 
United Kingdom 4 0 115 31 13 5 7 0 
Uruguay 1 0 0 12 1 0 0 0 
U.S.A. 15 1 1614 561 192 8 9 0 
